The company Vetbiohim, which has localized production in the special economic zone (SEZ) Technopolis Moscow, has developed an import-substituting inactivated vaccine Combovak Endomast against infectious diseases in cows. It is analogous to foreign drugs, but costs less. This was reported by Vladislav Ovchinsky, the head of the Department of Investment and Industrial Policy, which is part of a complex of economic policy and property and land relations of the capital. The vaccine was developed in 2022 to reduce the incidence of mastitis and endometritis in cattle, they are mostly affected by highly productive individuals. These infections cause great economic losses because they lead to infertility of the cow and unusable milk, which can be harmful to human health. Even if an animal is successfully treated, which requires high financial expenses, the previous milk yield may not recover because of irreversible changes in mammary gland tissue. Today, the company produces 36 vaccines for farm and small domestic animals, four serums and immunoglobulin, and 56 types of disease diagnostic test systems. The company completed construction of a new plant on the Pechatniki site of the special economic zone in Moscow in December 2022 and invested 1.6 billion rubles in the launch of the enterprise. The production of several tens of millions of doses of vaccines will help provide the Russian veterinary market with in-demand domestically produced drugs. In 2022 alone the company registered four new vaccines and set up their production, explained Vladislav Ovchinsky. According to the developers, Combovak Endomast preparation is simple and convenient to use, easily fits into the schedule of scheduled vaccinations against infectious diseases of large and small livestock farms. Vaccination of cows against infectious mastitis and endometritis is one of the most effective methods of preventing these diseases. The drug developed by Vetbiohim increases productivity and preservation of dairy herds, which provides a high economic effect. The Russian innovative vaccine is not inferior to foreign analogues, but it has a lower cost and therefore in demand in the market, said Gennady Dyogtev, General Director of SEZ Technopolis Moscow. According to Alexander Krivonos, Director General of Vetbiokhim, the innovation of the drug and its novelty lies in the unique composition of antigens that ensure high efficiency and harmlessness to animals. The vaccine induces long-term immunity after use, reduces the incidence of disease in dairy herds and improves milk quality. Companies that decide to locate production on the territory of the special economic zone Technopolis Moscow can obtain the status of a resident of the SEZ, which entitles them to significant benefits. Such enterprises are exempt from property, transport and land taxes for 10 years. The rate of profit tax for them is only two per cent. Residents can also rent land at a reduced rate. In addition, SEZ Technopolis Moscow has a free customs zone regime. ________________________________________ Press service of the SEZ "Technopolis Moscow" Phone: +7 916 516-15-46 Mail: pr@technomoscow.ru [ mailto:pr@technomoscow.ru ] Subscribe to the SEZ "Technopolis Moscow" in social networks, follow the main news of the SEZ in telegram-channel [ https://t.me/technopolismoscow ] and receive all the most important news delivered to your mail in our weekly newsletter [ http://events.technomoscow.ru/subscribe/?utm_source=site_technomoscow ] .
